Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205887777> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3205887777 endingPage "S164" @default.
- W3205887777 startingPage "S164" @default.
- W3205887777 abstract "Psoriasis is a chronic inflammatory disease, immune - mediated, with multisystemic implications and genetic predisposition, characterized by the development of erythematous, scaling plaques on the skin. The current therapy with biologic agents induces long term remissions in patients with moderate or severe psoriasis vulgaris, who are not responding to the conventional systemic therapy. Risankizumab is a humanised immunoglobulin G1 monoclonal antibody selective to the interleukin (IL)-23. We are presenting the case of a 71-year-old male patient, smoker, known with generalized psoriasis vulgaris, multiple bio-experienced who was referred to our Clinic for the occurrence of an eruption constituted by well-defined erythematous-squamous plaques and placards, pruritic, disseminated at the level of the whole body, occured in the context of discontinuation of biologic treatment for a period of 5 months due to the pandemic. Psoriasis Area Severity Index (PASI) upon hospitalization was 24,2. The treatment with risankizumab was initiated and we observed a very fast response, the evolution after 4 weeks was favorable, achieving PASI 2 and DLQI 0, with improving skin lesions and pruritus resolution. Being in front of a multiple bio “failure” patient (adalimumab, etanercept, ixekizumab, ustekinumab) we expected a modest response to therapy. However, the evolution was spectacular with PASI 2 four weeks after initiating the therapy with risankizumab. We also observed that treatment with IL-23 inhibitor was superior to both TNF-alpha blockers and IL-17 inhibitors to which the patient did not react, as well as ustekinumab, a monoclonal antibody that blocks the p40 subunit, common IL-12/23 to which he partially reacted and lost the response. In conclusion, although the patient was being treated with ustekinumab, a drug similar in structure and effect to risankizumab, the IL-23 inhibitor acting specifically on the p19 subunit had a very good and rapid response." @default.
- W3205887777 created "2021-10-25" @default.
- W3205887777 creator A5001250497 @default.
- W3205887777 creator A5008703363 @default.
- W3205887777 creator A5009421355 @default.
- W3205887777 creator A5041417174 @default.
- W3205887777 creator A5065547739 @default.
- W3205887777 date "2021-10-01" @default.
- W3205887777 modified "2023-10-18" @default.
- W3205887777 title "095 Therapeutic conduct in multiple bio-experienced psoriatic patient" @default.
- W3205887777 doi "https://doi.org/10.1016/j.jid.2021.08.097" @default.
- W3205887777 hasPublicationYear "2021" @default.
- W3205887777 type Work @default.
- W3205887777 sameAs 3205887777 @default.
- W3205887777 citedByCount "0" @default.
- W3205887777 crossrefType "journal-article" @default.
- W3205887777 hasAuthorship W3205887777A5001250497 @default.
- W3205887777 hasAuthorship W3205887777A5008703363 @default.
- W3205887777 hasAuthorship W3205887777A5009421355 @default.
- W3205887777 hasAuthorship W3205887777A5041417174 @default.
- W3205887777 hasAuthorship W3205887777A5065547739 @default.
- W3205887777 hasBestOaLocation W32058877771 @default.
- W3205887777 hasConcept C151730666 @default.
- W3205887777 hasConcept C16005928 @default.
- W3205887777 hasConcept C17991360 @default.
- W3205887777 hasConcept C203014093 @default.
- W3205887777 hasConcept C2776260265 @default.
- W3205887777 hasConcept C2777011040 @default.
- W3205887777 hasConcept C2777226972 @default.
- W3205887777 hasConcept C2778975655 @default.
- W3205887777 hasConcept C2779343474 @default.
- W3205887777 hasConcept C2779745271 @default.
- W3205887777 hasConcept C2779786854 @default.
- W3205887777 hasConcept C2780132546 @default.
- W3205887777 hasConcept C2780564577 @default.
- W3205887777 hasConcept C71924100 @default.
- W3205887777 hasConcept C86803240 @default.
- W3205887777 hasConceptScore W3205887777C151730666 @default.
- W3205887777 hasConceptScore W3205887777C16005928 @default.
- W3205887777 hasConceptScore W3205887777C17991360 @default.
- W3205887777 hasConceptScore W3205887777C203014093 @default.
- W3205887777 hasConceptScore W3205887777C2776260265 @default.
- W3205887777 hasConceptScore W3205887777C2777011040 @default.
- W3205887777 hasConceptScore W3205887777C2777226972 @default.
- W3205887777 hasConceptScore W3205887777C2778975655 @default.
- W3205887777 hasConceptScore W3205887777C2779343474 @default.
- W3205887777 hasConceptScore W3205887777C2779745271 @default.
- W3205887777 hasConceptScore W3205887777C2779786854 @default.
- W3205887777 hasConceptScore W3205887777C2780132546 @default.
- W3205887777 hasConceptScore W3205887777C2780564577 @default.
- W3205887777 hasConceptScore W3205887777C71924100 @default.
- W3205887777 hasConceptScore W3205887777C86803240 @default.
- W3205887777 hasIssue "10" @default.
- W3205887777 hasLocation W32058877771 @default.
- W3205887777 hasOpenAccess W3205887777 @default.
- W3205887777 hasPrimaryLocation W32058877771 @default.
- W3205887777 hasRelatedWork W2007444191 @default.
- W3205887777 hasRelatedWork W2785533887 @default.
- W3205887777 hasRelatedWork W2901240458 @default.
- W3205887777 hasRelatedWork W2984218665 @default.
- W3205887777 hasRelatedWork W3025568817 @default.
- W3205887777 hasRelatedWork W3183768684 @default.
- W3205887777 hasRelatedWork W3202364329 @default.
- W3205887777 hasRelatedWork W4213351251 @default.
- W3205887777 hasRelatedWork W4220980231 @default.
- W3205887777 hasRelatedWork W2756500207 @default.
- W3205887777 hasVolume "141" @default.
- W3205887777 isParatext "false" @default.
- W3205887777 isRetracted "false" @default.
- W3205887777 magId "3205887777" @default.
- W3205887777 workType "article" @default.